Wedbush Reaffirms Outperform Rating for TScan Therapeutics (NASDAQ:TCRX)

Wedbush reiterated their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report released on Monday morning,RTT News reports. Wedbush currently has a $7.00 price target on the stock.

A number of other equities research analysts also recently weighed in on TCRX. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a report on Wednesday, December 11th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of TScan Therapeutics in a research note on Wednesday, December 11th.

TScan Therapeutics Stock Down 3.3 %

TCRX opened at $2.91 on Monday. The stock’s fifty day simple moving average is $4.41 and its 200 day simple moving average is $5.54. TScan Therapeutics has a 1-year low of $2.60 and a 1-year high of $9.69. The stock has a market cap of $155.31 million, a PE ratio of -2.75 and a beta of 0.79. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The company had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.86 million. As a group, research analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Trading of TScan Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP acquired a new position in shares of TScan Therapeutics in the 2nd quarter valued at approximately $70,000. The Manufacturers Life Insurance Company bought a new position in TScan Therapeutics in the second quarter valued at approximately $90,000. SG Americas Securities LLC acquired a new position in TScan Therapeutics during the third quarter valued at approximately $78,000. XTX Topco Ltd bought a new stake in TScan Therapeutics during the third quarter worth $112,000. Finally, Cornercap Investment Counsel Inc. acquired a new stake in shares of TScan Therapeutics in the 2nd quarter valued at $134,000. 82.83% of the stock is currently owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.